- Supported exchanges /
- NASDAQ /
- SRZNW.NASDAQ
Surrozen Inc. Warrant (SRZNW NASDAQ) stock market data APIs
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Surrozen Inc. Warrant Financial Data Overview
0.0113 | |
0.0113 | |
- | |
0.0113 | |
0.0113 | |
0.0084-0.0888 | |
0 | |
0 | |
12 500 K | |
0.941 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Surrozen Inc. Warrant Fundamental Data is available in our Financial Data APIs
- Net Revenue 12 500 K
- EBITDA -35 835 000
- Earnings Per Share -5.695
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Surrozen Inc. Warrant Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Surrozen Inc. Warrant End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: